Olanzapine

證據等級: L5

預測適應症: 3 個

Olanzapine: From Schizophrenia to Benign Paroxysmal Torticollis of Infancy

One-Sentence Summary

Olanzapine is a well-established atypical antipsychotic, originally used to treat schizophrenia and bipolar I disorder. The TxGNN model predicts it may be effective for Benign Paroxysmal Torticollis of Infancy, with a very high model score (99.54%) but no clinical trials and no published literature currently supporting this specific link.

Quick Overview

Item	Content
Original Indication	Schizophrenia / Bipolar I Disorder (general drug-class knowledge; no South African registration data available — drug not marketed locally)
Predicted New Indication	Benign paroxysmal torticollis of infancy
TxGNN Prediction Score	99.54%
Evidence Level	L5 (model prediction only — no clinical trials or literature identified)
South Africa Market Status	Not marketed
Number of SAHPRA Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for this evidence pack. Based on known information, olanzapine is a second-generation (atypical) antipsychotic of the thienobenzodiazepine class, acting primarily as an antagonist at dopamine D2 and serotonin 5-HT2A receptors, with additional affinity for histaminergic, muscarinic and adrenergic receptors. Its efficacy in schizophrenia and bipolar I disorder is well established.

Benign paroxysmal torticollis of infancy is a rare, self-limiting episodic disorder in infants, generally considered a migraine-variant/vestibular condition rather than a primary psychotic or mood disorder. There is no established pharmacological rationale connecting an adult antipsychotic’s dopaminergic/serotonergic mechanism to this pediatric paroxysmal condition, and no clinical or case-report literature was returned for this drug-disease pair.

Given the absence of any supporting evidence and the substantial mismatch in patient population (adult psychiatric indication vs. infantile paroxysmal disorder), this prediction should be treated as a purely model-generated signal requiring independent mechanistic and safety review before any further consideration — olanzapine has no established pediatric safety profile for this age group.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

South Africa Market Information

Olanzapine currently has 0 SAHPRA registrations and is not marketed in South Africa. No product, dosage form, or approved-indication data is available for the local market.

Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.

Conclusion and Next Steps

Decision: Hold

Rationale: The top-ranked prediction (benign paroxysmal torticollis of infancy) is supported only by the TxGNN model score, with zero clinical trials and zero literature evidence, and involves a pediatric population for which olanzapine has no established safety profile. There is insufficient basis to advance this candidate.

To proceed, the following is needed:

Mechanism of action (MOA) and toxicology data for olanzapine (currently flagged as a Blocking data gap — TFDA/SAHPRA PI warnings and contraindications)
Independent mechanistic or preclinical rationale linking olanzapine to benign paroxysmal torticollis of infancy
Pediatric safety and pharmacokinetic data, given the target population is infants
Note: a separate candidate in this evidence pack — agoraphobia (TxGNN score 99.47%, 7 supporting PubMed publications including an open-label trial of olanzapine augmentation in treatment-resistant panic disorder with agoraphobia) — has materially stronger literature support and may warrant its own evaluation as a higher-priority repurposing candidate
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.